Journal
JOURNAL OF CLINICAL LIPIDOLOGY
Volume 15, Issue 3, Pages 512-521Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2021.02.005
Keywords
PCSK9; Inflammation; Atherosclerosis; Coronary artery disease; Monocytes
Categories
Funding
- FWF Austrian Science Fund [SFB54]
- Association for the Promotion of Research on Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
- Ludwig Boltzmann Institute for Cardiovascular Research
Ask authors/readers for more resources
This study found that in patients with stable coronary artery disease, those on statin treatment had higher levels of PCSK9. Among patients on statin treatment, classical monocytes were positively correlated with PCSK9 levels, while non-classical monocytes were negatively correlated with PCSK9 levels. Additionally, patients with PCSK9 levels above the median had a higher proportion of classical monocytes.
Background: Proprotein convertase subtilisin/kexin type-9 (PCSK9) is an enzyme promoting the degradation of low-density lipoprotein receptors (LDL-R) in hepatocytes. Inhibition of PCSK9 has emerged as a novel target for lipid-lowering therapy. Monocytes are crucially involved in the pathogenesis of atherosclerosis and can be divided into three subsets. Objective: The aim of this study was to examine whether circulating levels of PCSK9 are associated with monocyte subsets. Methods: We included 69 patients with stable coronary artery disease. PCSK9 levels were measured and monocyte subsets were assessed by flow cytometry and divided into classical monocytes (CD14++CD16-; CM), intermediate monocytes (CD14++CD16+; IM) and non-classical monocytes (CD14+CD16++; NCM). Results: Mean age was 64 years and 80% of patients were male. Patients on statin treatment (n = 55) showed higher PCSK9-levels (245.4 (206.0-305.5) ng/mL) as opposed to those without statin treatment (186.1 (162.3-275.4) ng/mL; p = 0.05). In patients on statin treatment, CM correlated with circulating PCSK9 levels (R = 0.29; p = 0.04), while NCM showed an inverse correlation with PCSK9 levels (R = -0.33; p = 0.02). Patients with PCSK9 levels above the median showed a significantly higher proportion of CM as compared to patients with PCSK9 below the median (83.5 IQR 79.2-86.7 vs. 80.4, IQR 76.5-85.2%; p = 0.05). Conversely, PCSK9 levels >median were associated with a significantly lower proportion of NCM as compared to those with PCSK9
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available